AP285A - Pharmaceutical composition comprising a particular pysical form of a heterocyclic amide derivative. - Google Patents

Pharmaceutical composition comprising a particular pysical form of a heterocyclic amide derivative. Download PDF

Info

Publication number
AP285A
AP285A APAP/P/1991/000340A AP9100340A AP285A AP 285 A AP285 A AP 285A AP 9100340 A AP9100340 A AP 9100340A AP 285 A AP285 A AP 285A
Authority
AP
ARIPO
Prior art keywords
vhich
physical form
methyl
amino
composition
Prior art date
Application number
APAP/P/1991/000340A
Other languages
English (en)
Other versions
AP9100340A0 (en
Inventor
James Joseph Holohan
Ieuan John Edwards
Robert Joseph Timko
Randy John Bradway
Arlene Clements
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP285(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909027014A external-priority patent/GB9027014D0/en
Priority claimed from GB919115107A external-priority patent/GB9115107D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of AP9100340A0 publication Critical patent/AP9100340A0/xx
Application granted granted Critical
Publication of AP285A publication Critical patent/AP285A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
APAP/P/1991/000340A 1990-12-12 1991-12-11 Pharmaceutical composition comprising a particular pysical form of a heterocyclic amide derivative. AP285A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909027014A GB9027014D0 (en) 1990-12-12 1990-12-12 Pharmaceutical agents
GB919115107A GB9115107D0 (en) 1991-07-12 1991-07-12 Pharmaceutical agents

Publications (2)

Publication Number Publication Date
AP9100340A0 AP9100340A0 (en) 1992-01-31
AP285A true AP285A (en) 1993-09-23

Family

ID=26298105

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1991/000340A AP285A (en) 1990-12-12 1991-12-11 Pharmaceutical composition comprising a particular pysical form of a heterocyclic amide derivative.

Country Status (30)

Country Link
US (6) US5319097A (zh)
EP (1) EP0490648B1 (zh)
JP (1) JP2585495B2 (zh)
KR (2) KR0183027B1 (zh)
CN (2) CN1043405C (zh)
AP (1) AP285A (zh)
AT (1) ATE131048T1 (zh)
AU (1) AU656157B2 (zh)
BE (1) BE1004229A5 (zh)
CA (2) CA2056066C (zh)
CZ (1) CZ283181B6 (zh)
DE (2) DE4140858A1 (zh)
DK (1) DK0490648T3 (zh)
ES (1) ES2079589T3 (zh)
FI (1) FI101193B1 (zh)
FR (1) FR2670488B1 (zh)
GB (2) GB2280606B (zh)
GR (1) GR3018318T3 (zh)
HK (2) HK81397A (zh)
HU (2) HU213211B (zh)
IE (1) IE75348B1 (zh)
IL (1) IL100091A (zh)
IT (1) IT1256282B (zh)
MX (1) MX9102473A (zh)
MY (1) MY106315A (zh)
NZ (1) NZ240939A (zh)
PH (1) PH30928A (zh)
RU (1) RU2106140C1 (zh)
SK (2) SK279813B6 (zh)
TW (1) TW276181B (zh)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
GB9119001D0 (en) * 1991-09-05 1991-10-23 Ici Plc Pharmaceutical agents
GR1001368B (el) * 1992-10-08 1993-10-29 Ici Plc Φαρμακευτικοί φορείς.
DE4235133A1 (de) * 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
DE9410461U1 (de) * 1994-07-01 1994-09-22 Merck Patent Gmbh, 64293 Darmstadt Mittel für die Röntgenfluoreszenzanalyse
US6279736B1 (en) 1995-04-19 2001-08-28 Capitol Specialty Plastics, Inc. Barrier pack having an absorbing agent applied to the interior of the pack
IN182496B (zh) * 1996-02-20 1999-04-17 Reddy Research Foundation
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
GB9723985D0 (en) 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6224907B1 (en) 1998-03-06 2001-05-01 Alza Corporation Anti-asthma therapy
KR100283682B1 (ko) * 1998-07-14 2001-03-02 조정래 열풍건조장치
US6253463B1 (en) 1999-04-26 2001-07-03 Niro A/S Method of spray drying
IN191496B (zh) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
AU1188601A (en) * 1999-09-20 2001-04-24 Alza Corporation Process for lessening polymorphic conversion of a drug
IL139243A0 (en) * 2000-10-24 2001-11-25 Internat Specialty Products Is Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof
IL140096A0 (en) * 2000-12-05 2002-02-10 Internat Specialty Products Is Process for preparation of zafirlukast
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
ATE374641T1 (de) * 2001-01-26 2007-10-15 Schering Corp Kombinationen vom ppar-aktivator fenofibrat mit dem hemmer der sterol-absorption ezetimibe zur behandlung von kardiovaskulären indikationen
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
JP2005502628A (ja) * 2001-07-10 2005-01-27 ファルマシア・アンド・アップジョン・カンパニー 結晶性チアジンオキサゾリジノン
GEP20063777B (en) * 2001-08-15 2006-03-27 Upjohn Co Crystals Including Malic Acid Salt of N-[2-(Diethylamino) Ethyl]-5-[(5-Fluoro-2-Oxo-3h-Indole-3-Ylidene) Methyl]-2, 4-Dimethyl-1h-Pyrrole-3-Carboxamide, Processes for Its Preparation and Compositions Thereof
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
PT1429756E (pt) * 2001-09-21 2007-01-31 Schering Corp Tratamento de xantoma com derivados de azetidinona como inibidores de absorção de esteróis
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
WO2004081003A1 (en) * 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ES2311806T3 (es) * 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
US20070197467A1 (en) * 2006-02-06 2007-08-23 Srinivasulu Rangineni Zafirlukast compositions
US20090012146A1 (en) * 2007-07-02 2009-01-08 Giridhar Reddy Buggana Solubility-enhanced pharmaceutical compositions comprising zafirlukast
US20090191183A1 (en) * 2007-07-30 2009-07-30 Auspex Pharmaceuticals, Inc. Substituted indoles
US20090149662A1 (en) * 2007-12-05 2009-06-11 Raghupathi Reddy Anumula Processes for preparing zafirlukast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
WO2015110394A1 (en) 2014-01-22 2015-07-30 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
PT109030B (pt) 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
EP3585809A4 (en) 2017-01-30 2021-02-24 Western New England University THIOLISOMERASE INHIBITORS AND USES THEREOF
US10752585B2 (en) 2017-12-28 2020-08-25 Council Of Scientific & Industrial Research Process for the preparation of Zafirlukast and analogs thereof
CN117999074A (zh) 2021-05-19 2024-05-07 奎尔塞斯制药股份公司 用于治疗肌萎缩侧索硬化症的含有槲皮素的组合物
WO2023214391A1 (en) 2022-05-06 2023-11-09 Quercis Pharma AG Method for treating cancers and neurological diseases using quercetin-containing compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
GB9027018D0 (en) * 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NONE *

Also Published As

Publication number Publication date
ES2079589T3 (es) 1996-01-16
AP9100340A0 (en) 1992-01-31
MY106315A (en) 1995-04-29
FR2670488A1 (fr) 1992-06-19
CZ283181B6 (cs) 1998-01-14
IE914310A1 (en) 1992-06-17
KR0183027B1 (ko) 1999-05-01
PH30928A (en) 1997-12-23
CA2319308C (en) 2001-08-21
NZ240939A (en) 1994-05-26
EP0490648B1 (en) 1995-12-06
FI915826A0 (fi) 1991-12-11
IT1256282B (it) 1995-11-29
GB9126354D0 (en) 1992-02-12
HU211126A9 (en) 1995-10-30
SK279813B6 (sk) 1999-04-13
GB2280606A (en) 1995-02-08
IE75348B1 (en) 1997-08-27
KR100207802B1 (ko) 1999-07-15
GR3018318T3 (en) 1996-03-31
AU656157B2 (en) 1995-01-27
SK279814B6 (sk) 1999-04-13
ATE131048T1 (de) 1995-12-15
US6143775A (en) 2000-11-07
ITMI913324A1 (it) 1993-06-11
CA2056066A1 (en) 1992-06-13
US5612367A (en) 1997-03-18
FR2670488B1 (fr) 1994-01-28
AU8899491A (en) 1992-06-18
US5319097A (en) 1994-06-07
DE4140858A1 (de) 1992-06-17
TW276181B (zh) 1996-05-21
HUT61281A (en) 1992-12-28
FI101193B (fi) 1998-05-15
KR920011493A (ko) 1992-07-24
FI101193B1 (fi) 1998-05-15
JPH04266824A (ja) 1992-09-22
HU913865D0 (en) 1992-02-28
DE69115229D1 (de) 1996-01-18
CN1062291A (zh) 1992-07-01
GB2280606B (en) 1995-05-17
IL100091A0 (en) 1992-08-18
IL100091A (en) 1998-08-16
FI915826A (fi) 1992-03-31
CS375691A3 (en) 1992-06-17
RU2106140C1 (ru) 1998-03-10
GB9418154D0 (en) 1994-10-26
HK81597A (en) 1997-06-27
CA2056066C (en) 2002-04-02
DE69115229T2 (de) 1996-05-09
CN1043405C (zh) 1999-05-19
EP0490648A1 (en) 1992-06-17
KR970005014A (ko) 1997-01-29
ITMI913324A0 (it) 1991-12-11
HK81397A (en) 1997-06-27
US5482963A (en) 1996-01-09
MX9102473A (es) 1992-06-01
DK0490648T3 (da) 1996-05-06
HU213211B (en) 1997-03-28
CN1105705C (zh) 2003-04-16
GB2251791B (en) 1995-05-17
CN1243827A (zh) 2000-02-09
GB2251791A (en) 1992-07-22
CA2319308A1 (en) 1992-06-13
US5504216A (en) 1996-04-02
JP2585495B2 (ja) 1997-02-26
BE1004229A5 (fr) 1992-10-13
US5993859A (en) 1999-11-30

Similar Documents

Publication Publication Date Title
AP285A (en) Pharmaceutical composition comprising a particular pysical form of a heterocyclic amide derivative.
JP4282092B2 (ja) 多形性化合物
CA2056067C (en) A physical form of n-¬4-¬5-(cyclopentyloxcarbony)-amino-1-methylindol-3-yl-methyi|-3-methoxybenzoy1|-2-methyibezenesulphonanide, processes for its preparation and compositions containing it
AU3095600A (en) New pharmaceutical formulation
JP3995414B2 (ja) 安定な医薬組成物
CA2532351A1 (en) Stable modifications of tegaserod hydrogen maleate
FI106021B (fi) Menetelmä N-[4-[5-(syklopentyylioksikarbonyyli)amino-1-metyyli-indol-3-yyli-metyyli]-3-metoksibentsoyyli]-2-metyylibentseenisulfonamidin fysikaalisen muodon valmistamiseksi
WO2021097650A1 (zh) 奥利司他与氨基酸的共晶体及包含该共晶体的药物组合物
NO179575B (no) Farmasöytisk preparat inneholdende en fysikalsk form av forbindelsen N-[4-[5-(cyklopentyloksykarbonyl)amino-1-metylindol-3-ylmetyl-3-metoksybenzoylÅ-2-metylbenzensulfonamid
PT100508B (pt) Composicoes farmaceuticas e processo para a sua preparacao
SK7362002A3 (en) Solid pharmaceutical preparation
HU220769B1 (hu) N-[ 4-(5-/Ciklopentil-oxi-karbonil-amino/-l-metil-indol-3-il-metil)-3-metoxi-benzoil]-2-metil-benzolszulfonamid új fizikai módosulata és eljárás annak előállítására
NO179248B (no) Fysikalsk form av N-[4-[5-(cyklopentyloksykarbonyl)amino-1-metylindol-3-ylmetylÅ-3-metoksybenzoylÅ-2-metylbenzensulfonamid og fremgangsmåte for fremstilling derav